- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for Zalicus Inc (ZLCS)
| Open: | 0.6300 | Day's Range: | 0.6000 - 0.6300 | Volume: | 710,370 |
|---|---|---|---|---|---|
| Previous Close: | 0.6200 | 52wk Range: | 0.4300 - 1.6200 | 1-Yr Rtn: | -22.07% |
Key Statistics for ZLCS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.3100 |
| Est. EPS (USD) (12/2013) | -0.2670 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 76.36 |
| Shares Outstanding (M) | 127.26 |
| 30 Day Average Volume | 721,703 |
| Price/Book (mrq) | 3.2488 |
| Price/Sale (ttm) | 5.3258 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ZLCS
Company Profile & Key Executives for ZLCS
Zalicus Inc is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The Company's drug pipeline includes an arthritis formula in phase 2 development.
| Mark H N CorriganPresident/CEO | Justin A RenzExec VP/CFO/Treasurer |
| Jason F ColeExec VP:Corporate Dev/Gen Cnsl |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ZLCS News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page